CVrg’s Cardiovascular & Metabolic (CVM) market reports cover Acute Coronary Syndrome (ACS), Atrial Fibrillation (AFib/SPAF), Chronic Kidney Disease (CKD), Dyslipidemia / Atherosclerosis (Dys/Ath), Non-Alcoholic Fatty Liver (NAFL/NASH), Heart Failure (HF), Peripheral Arterial Disease (PAD), Pulmonary Hypertension (PH), Obesity, Type 1 Diabetes (T1D), and Type 2 Diabetes (T2D), and Venous Thrombosis (VT).
A new paradigm continues to evolve in these markets with more restricted market access and an increasing number of commercialization barriers. At the same time, BioPharma companies have less financial resources to invest in these areas, so they are systematically focusing individual, team and franchise efforts on the most promising product opportunities in carefully selected markets. These companies are also building on the overlap of pathologically connected indications so they can maximize their investments. These complexities set up a unique market landscape and provide exciting opportunities for the development of products aimed at treating underlying pathogenesis with the potential to affect large patient populations.
CVrg addresses these market challenges through conducting expert primary research and rigorous secondary analysis, delivering practical and strategic assessments of opportunities and threats in the unique environment of risk factor treatment, and offering different packages that meet specific client needs. We stand ready to serve our clients with expert resources unmatched in scope, depth, and accuracy in the CVM markets. We do this through the following points of entry… login for more details.